The new offering, designed to enhance diabetes trials, combines wearable technology with Quintiles' therapeutic and analytical expertise.
Quintiles announced a new service offering designed to improve diabetes-focused clinical trials. Through the solution, continuous glucose measurements will be monitored by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day. In the clinical trial setting, such comprehensive and timely glucose visibility can potentially improve patient safety, accelerate clinical development, and provide a basis for differentiated claims.
Read the full release here
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.